Preclinical studies with MEK inhibitors reported that BRAF mutant melanoma cells growing both in vitro and in vivo as xenografts were more responsive to MEK inhibition than cell lines with wild type BRAF status (Davies et al., 2002; Solit et al., 2006). The gene discussed is MAP2K7; the disease is melanoma.